Recent advances in novel targeted therapies for HER2-positive breast cancer.
about
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast CancerTumor imaging and targeting potential of an Hsp70-derived 14-mer peptide.Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.OSU-03012 interacts with lapatinib to kill brain cancer cellsPersonalizing health care: feasibility and future implications.Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of originUtility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.Antitumor activity of SA12, a novel peptide, on SKBr-3 breast cancer cells via the mitochondrial apoptosis pathwayDownregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifenConstruction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuHER2 as a target in invasive urothelial carcinoma.FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal CarcinomaAdaptive Immune Responses and HER2/neu Positive Breast Cancer.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.The genomic map of breast cancer: which roads lead to better targeted therapies?Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Clinical relevance of target identity and biology: implications for drug discovery and development.New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.Brain metastases in breast cancer.The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws?Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Functional assessment of MeCP2 in Rett syndrome and cancers of breast, colon, and prostate.Advances in Targeting HER3 as an Anticancer TherapyEffects of local irradiation combined with sunitinib on early remodeling, mitochondria, and oxidative stress in the rat heartIdentifying the challenges of biomarkers that predict response to HER2-directed therapies.PI3K inhibition to overcome endocrine resistance in breast cancer.Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients.Novel inhibitors of breast cancer relevant kinases Brk and HER2
P2860
Q33430735-0A2AF93E-E81C-4E22-A60A-673D1F3915B5Q33576608-F9F6EDC8-8136-42F8-9417-2BD9AB9CCCD8Q34104760-4084F37E-FB65-4767-91D4-BDDA641C3F9EQ34253243-C1182EBC-BD9D-41BD-9597-01D78A918DF9Q34300517-05F35FD2-BA45-497E-A955-963B5AE3D4CEQ34938911-ABE3E4E8-16F7-49EA-9822-98752ADCE062Q34959996-101C4129-E275-43F8-9B2B-9327EB9E740BQ35031049-93E49146-C701-4EB7-9D2F-6FAE592AF648Q35161655-F539ADB5-5931-4B76-AB89-DC2BC12D7E39Q35402408-8F5FF0E3-9D68-4D4A-A22E-1391754D6FE7Q35541200-0503D6DE-B995-4DEB-8AE4-D6F1994C6B36Q35755382-FFA219AD-3EC6-4111-9E50-03C7E7442B30Q35837391-1CE5BCEB-9650-4743-A568-9F2713524093Q36607857-FB596A35-D2CE-4295-B579-E6759F5EFD79Q36854062-7D1D8A44-8829-4E86-A271-7DDE3CAB1FCCQ37522215-82E2E3E7-2880-484D-A9CB-BED1FD05BBC6Q37691054-62879487-2985-4D8C-9A37-6F146D81E48AQ38064285-8482DFA4-879F-40B7-8983-AB603A6C6CA9Q38076053-C3FC9767-0D6A-4B45-9254-97B0F0D74686Q38147723-B9C6580F-4AF2-41F3-BB69-72E5F4159E86Q38152315-F2FF33BE-8CCE-4236-A78F-8F6E840847D5Q38168924-4716AF7B-27D8-4475-9EFC-F3B7C8A6E2B5Q38254375-1EFDEDD5-433C-414D-AE43-F59E9111AC85Q38852051-BF6481B4-0851-4BA8-A7CF-F45F9C0AF53FQ39126183-4F6DE73F-EADF-46A5-B4B7-238CE8E93679Q41621146-A050F37D-A1AD-49FC-82C7-BB84343777ADQ41902920-06A84205-A79B-4664-BB5B-5D8FB686EDA7Q43628088-979C3531-D2BE-4F1F-9F65-FF71EA39F4D5Q47776273-ED214603-7710-4E28-8CE6-561B0402A87EQ47813594-4E00D426-E0A7-4BA6-A713-F701F647C255Q50943615-E1D8680E-2D1F-4EB8-A9E9-0911EBD0E0E3Q54361340-112305CD-2D73-4E42-BE63-C5762409EA27Q58860058-E6D56050-25E3-46E2-A245-50B7EF154957
P2860
Recent advances in novel targeted therapies for HER2-positive breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recent advances in novel targeted therapies for HER2-positive breast cancer.
@en
type
label
Recent advances in novel targeted therapies for HER2-positive breast cancer.
@en
prefLabel
Recent advances in novel targeted therapies for HER2-positive breast cancer.
@en
P1433
P1476
Recent advances in novel targeted therapies for HER2-positive breast cancer.
@en
P2093
Conleth G Murphy
Patrick G Morris
P304
P356
10.1097/CAD.0B013E328352D292
P577
2012-09-01T00:00:00Z